Sino Biopharmaceutical Limited has announced the completion of subject enrollment in a Phase III clinical trial of its investigational drug TQB2102, a HER2 bispecific antibody-drug conjugate $(ADC)$, for the treatment of HER2-low recurrent or metastatic breast cancer. The trial, titled "Randomised, Open-label, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-selected Chemotherapy in HER2-Low Recurrent/Metastatic Breast Cancer (TQB2102-III-01)," aims to assess the efficacy and safety of TQB2102 compared to standard chemotherapy options. TQB2102 is described as a next-generation HER2 dual-epitope bispecific ADC developed by the company. Results from this Phase III trial have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260210-12019960), on February 09, 2026, and is solely responsible for the information contained therein.